text
"['\n3. 타법인출자 현황(상세)\n☞ 본문 위치로 이동\n(기준일 :\xa0\n2023년 12월 31일\n)\n(단위 : 백만원, 주, %)\n법인명\n상장여부\n최초취득일자\n출자목적\n최초취득금액\n기초잔액\n증가(감소)\n기말잔액\n최근사업연도재무현황\n수량\n지분율\n장부가액\n취득(처분)\n평가손익\n수량\n지분율\n장부가액\n총자산\n당기순손익\n수량\n금액\n한국콜마(주)\n상장\n2012.10.02\n경영참여\n112,434\n6,209,889\n27.14\n265,441\n-\n-\n-\n6,209,889\n27.14\n265,441\n3,009,429\n25,139\n콜마비앤에이치(주)\n상장\n2004.02.26\n경영참여\n510\n13,129,267\n44.44\n15,569\n-\n-\n-\n13,129,267\n44.44\n15,569\n694,467\n18,736\n모노랩스(주)\xa0\n비상장\n2018.08.09\n단순투자\n250\n4,280\n2.90\n250\n-\n-\n-\n4,280\n2.90\n250\n10,788\n-3,643\n에이치케이바이오이노베이션㈜\n비상장\n2019.07.29\n경영참여\n20,397\n3,448,276\n57.00\n10,312\n-3,448,276\n10,312\n-\n-\n-\n-\n-\n45\n(주)넥스트앤바이오\n비상장\n2020.01.01\n경영참여\n1,012\n7,808\n46.31\n11,227\n-\n-\n2,075\n7,808\n46.31\n13,302\n8,089\n-5,012\n(주)플래닛147\n비상장\n2020.12.14\n경영참여\n3,800\n152,000\n100.00\n3,800\n-\n-\n-\n152,000\n100.00\n3,800\n3,558\n-896\n콜마글로벌(주)\xa0\n비상장\n2020.12.14\n경영참여\n10,000\n520,000\n100.00\n3,383\n120,000\n3,000\n-\n640,000\n100.00\n6,383\n7,404\n-3,065\nHK Innovers USA, Inc.\n비상장\n2022.06.09\n경영참여\n12\n10\n100.00\n12\n-\n-\n-\n10\n100.00\n12\n5\n-2\n콜마유엑스(주)\xa0\n비상장\n2022.07.01\n경영참여\n6,014\n60,000\n100.00\n6,014\n-\n-\n-\n60,000\n100.00\n6,014\n14,972\n397\n(주)농우바이오(주3)\n상장\n2014.10.23\n단순투자\n299\n11,800\n-\n102\n-\n-\n-3\n11,800\n-\n99\n323,809\n10,321\n네오아티잔(주)\xa0\n비상장\n2015.08.17\n단순투자\n1,000\n120,681\n4.02\n241\n-\n-\n-\n120,681\n4.02\n241\n9,575\n-488\n이노이브코리아㈜\n비상장\n2012.06.30\n단순투자\n200\n50,400\n16.24\n-\n-\n-\n-\n50,400\n16.24\n-\n-\n-\n(주)크레이버코퍼레이션 보통주\n비상장\n2018.10.23\n단순투자\n300\n4,731\n0.39\n-\n-\n-\n-\n4,731\n0.39\n-\n30,813\n10,393\n(주)크레이버코퍼레이션 RCPS\n비상장\n2018.10.23\n단순투자\n2,400\n32,171\n2.67\n375\n-\n-\n-\n32,171\n2.67\n375\n30,813\n10,393\nPRIMER SAZZE FUND Ⅰ(주5)\n비상장\n2019.12.11\n단순투자\n2,176\n2,500\n5.83\n2,882\n-\n-\n-\n2,500\n5.83\n2,882\n136,973\n49,786\n(주)비모뉴먼트\n비상장\n2020.07.21\n단순투자\n1,999\n88,532\n4.04\n4,388\n12,629\n1,026\n3,422\n101,161\n4.52\n8,836\n89,572\n26,421\n(주)컬쳐앤커머스(주5)\n비상장\n2021.05.17\n단순투자\n300\n28,251\n5.43\n343\n-\n-\n-\n28,251\n5.43\n343\n3,764\n-528\n(주)레이어즈\n비상장\n2021.04.22\n단순투자\n1,500\n50,000\n8.33\n740\n-\n-\n170\n50,000\n8.33\n910\n5,458\n-412\n(주)노바셀테크놀로지\n비상장\n2021.07.22\n단순투자\n1,000\n100,000\n0.97\n1,202\n-\n-\n142\n100,000\n0.97\n1,344\n6,264\n-3,090\n(주)셀인셀즈\n비상장\n2021.07.19\n단순투자\n2,000\n3,901\n4.01\n2,003\n-\n-\n-\n3,901\n4.01\n2,003\n6,594\n-5,144\n(주)지아이셀\n비상장\n2021.09.15\n단순투자\n5,000\n238,096\n1.95\n5,293\n-\n-\n1,132\n238,096\n1.95\n6,425\n35,212\n-25,639\n(주)다인메디컬그룹\n비상장\n2022.01.13\n단순투자\n1,002\n758\n10.71\n2,250\n-\n-\n159\n758\n10.71\n2,409\n10,488\n-2,168\n(주)럽맘\n비상장\n2022.05.26\n단순투자\n500\n200,000\n9.09\n522\n-\n-\n-\n200,000\n9.09\n522\n1,470\n101\n(주)올라운드닥터스\n비상장\n2022.06.02\n단순투자\n1,000\n15,008\n8.33\n1,000\n-\n-\n-\n15,008\n8.33\n1,000\n3,480\n-1,833\nMomenti Inc.(주2)(주5)\n비상장\n2022.04.19\n단순투자\n2,489\n-\n-\n8,999\n-\n-\n-\n-\n-\n8,999\n897\n-1,978\n(주)바이옴에이츠(주1)\n비상장\n2023.01.05\n단순투자\n500\n-\n-\n-\n1,500\n500\n-\n1,500\n6.66\n500\n1,429\n-749\nKB 글로벌 플랫폼 2호 펀드(주1)\n비상장\n2023.03.30\n단순투자\n800\n-\n-\n-\n-\n2,400\n-\n-\n-\n2,400\n58,384\n-4,139\n㈜라이프사이언스테크놀로지(보통주)(주1)\n비상장\n2023.02.28\n단순투자\n731\n-\n-\n-\n553,624\n731\n-\n553,624\n11.40\n731\n1,849\n-500\n㈜라이프사이언스테크놀로지(RCPS)(주1)\n비상장\n2023.02.28\n단순투자\n377\n-\n-\n-\n200,000\n377\n-\n200,000\n4.12\n377\n1,849\n-500\n안다H 프로젝트 일반사모투자신탁제8호(주1)(주6)\n비상장\n2023.05.09\n단순투자\n1,000\n-\n-\n-\n-\n1,423\n-600\n-\n-\n823\n-\n-\n아이비케이씨-마이다스 밸류크리에이션 신기술사업투자조합(주1)\n비상장\n2023.05.10\n단순투자\n95\n-\n-\n-\n-\n259\n-\n-\n-\n259\n12,565\n-1,044\n주식회사 브렉소젠(주1)\n비상장\n2023.08.22\n단순투자\n2,000\n-\n-\n-\n33,333\n2,000\n-\n33,333\n2.06\n2,000\n15,538\n-6,562\n파인트리 3호 펀드(주1)\n비상장\n2023.07.07\n단순투자\n1,500\n-\n-\n-\n-\n1,500\n-\n-\n-\n1,500\n22,668\n-472\n(주)레지에나(주1)\n비상장\n2023.12.28\n단순투자\n500\n-\n-\n-\n5,102\n500\n-\n5,102\n3.21\n500\n1,270\n-760\n(주)브레인유(주1)\n비상장\n2023.12.28\n단순투자\n500\n-\n-\n-\n11,730\n500\n-\n11,730\n2.38\n500\n2,195\n-342\n(주)넥스트앤바이오(주1)(주4)\n비상장\n2023.12.27\n단순투자\n3,000\n-\n-\n-\n1,176\n3,000\n-\n1,176\n1.43\n3,000\n8,089\n-5,012\n합 계\n24,478,359\n-\n346,348\n-2,509,182\n6,904\n6,497\n21,969,177\n-\n359,749\n4,569,730\n77,754\n(주1) 당기 중 신규투자 하였습니다.(주2) 피투자자가 후속 투자를 받는 경우, 계약에 따라 당사는 피투자자로부터 우선주를 발행 받기로 한 조건부 지분 인수계약입니다.(주3) 상기 지분상품은 지분율이 미미하므로 지분율의 표기를 생략하였습니다.(주4) 상환전환우선주 취득 건으로 당기손익-공정가치측정 금융자산으로 별도 분류했습니다.(주5) 최근사업연도 재무현황에 2022년의 총자산,당기순손익을 기재하였습니다.(주6) 법인이 아닌 금융자산의 성격으로 재무현황을 기재하지 않았습니다.\n']"
